Canakinumab

Study Links Key Gene to Protection from Severe Illness and Death From Covid Infections in Men Under Age 75

Retrieved on: 
Wednesday, March 13, 2024
Inflammation, Gene, Brain, Letter, Internal medicine, Rheumatoid arthritis, COVID-19, NYU Langone Health, Infection, Disease, Abramson, Risk, Patient, APG system, Journal, Research, IL1, Factorization of polynomials, Canakinumab, NYU, Death, Doctor of Philosophy, SARS-CoV-2, Attur, Salem, Arthritis, Woman, Male, MPH, National Institutes of Health, IL1RN, Vasopressin receptor 2, Bangladesh Technical Education Board, Fatigue, Blood, Viral, Hospital, Pharmaceutical industry

NEW YORK, March 13, 2024 /PRNewswire/ -- A certain variant of a key anti-inflammatory gene protects men under age 75 from severe illness and death when hospitalized from Covid-19, a genetic analysis of their blood shows.

Key Points: 
  • NEW YORK, March 13, 2024 /PRNewswire/ -- A certain variant of a key anti-inflammatory gene protects men under age 75 from severe illness and death when hospitalized from Covid-19, a genetic analysis of their blood shows.
  • According to the study authors, the protective gene in question, an interleukin-1 receptor antagonist (IL1RN) variant, appears to tamp down inflammation.
  • Overall, more men than women (240 men, at 60.5%; and 157 women, at 39.5%) died from their disease, with women 20% less likely to die than men.
  • Funding support for this study was provided by National Institutes of Health grants P30CA016087 and R21AR078466.

The lesser-known risk factors for heart disease

Retrieved on: 
Thursday, June 15, 2023
People, Heart, Longest NCAA Division I football winning streaks, Gout, Plaque, Smoking, Diet, Health, Canakinumab, Stroke, Cholesterol, Infection, Atherosclerosis, Cardiovascular disease, Clinical trial, Splenic infarction, Quality of life, Endothelium, Methotrexate, Grain boundary strengthening, Brain, Artery, Risk, Fruit, Cell, Inflammation, Vegetable, Obesity, Facial muscles, Psoriasis, Inflammatory bowel disease, Colchicine, Membrane protein, Rupture, Patient, Time, Blood, LDL, Immune system, Overweight, Fatty streak, Body mass index, Moyamoya disease, Coronary artery disease, Research, Exercise, The Cantos, Rheumatoid arthritis, Pharmaceutical industry, Medical imaging, Dietary supplement, Dentistry, ASCVD

Most people know that the risk factors for heart disease are high blood pressure, smoking, raised cholesterol and being overweight.

Key Points: 
  • Most people know that the risk factors for heart disease are high blood pressure, smoking, raised cholesterol and being overweight.
  • However, many people who have a heart attack do not have any of these traditional risk factors.
  • Research has suggested that conditions such as gout, psoriasis, inflammatory bowel disease and rheumatoid arthritis are also risk factors for heart disease.
  • Long-term inflammation of the arteries supplying the heart and brain can eventually lead to heart attacks and strokes.
  • Because this chronic inflammatory process happens silently, many patients without traditional risk factors for heart disease will not be aware that they are at an increased risk of heart disease.

Measuring inflammation

    • However, the study was considered groundbreaking in that it supported the hypothesis that inflammation plays an important role in ASCVD, and that targeting inflammation may be useful to reduce the risk of repeat cardiovascular events.
    • Also, this may enable us to focus on treating inflammation in order to reduce cardiovascular risk.
    • Already, several studies are looking at using cheaper anti-inflammatory drugs, such as colchicine and methotrexate, to reduce inflammation and prevent the progression of cardiovascular disease.

Lifestyle changes to reduce inflammation

    • Fortunately, it is possible to reduce inflammation in our bodies without resorting to drugs.
    • Losing weight around your midsection will help to reduce this inflammation.
    • By making anti-inflammatory choices and leading a healthy lifestyle we can all reduce our chances of developing heart disease and improve our quality of life.

Olatec Announces High-Impact Coverage of Dapansutrile in Leading Journal on Cardiovascular Disease as well as Another Publication from New Preclinical Data in a Heart Failure Model

Retrieved on: 
Tuesday, February 15, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Cardiology, Protein, Infarction, Prevalence, HF, NLRP3, Cardiology, Therapy, JACC, Inflammation, Model, LLC, SCI, Journal of Cardiovascular Pharmacology and Therapeutics, Company, Journal, Manuscript, Pharmacology, Virginia Commonwealth University, Compliance, Melanoma, Degenerative disease, Associate, Genetics, Industry, Cardiovascular disease, Oslo University Hospital, Review, American College, Infection, Heart failure, Myocardial infarction, Inflammasome, Mouse, Principal, Arthritis, Multiple sclerosis, Medical director, CVD, OLT, Asthma, Patient, Synthetic control method, Ischemic cardiomyopathy, Molecule, IP, Canakinumab, Press release, Ageing, Institute for Health Metrics and Evaluation, AMI, Reperfusion, Pharmaceutical industry, Medicine, Heart Failure, Dapansutrile, Olatec Therapeutics LLC, HEART FAILURE, DAPANSUTRILE, OLATEC THERAPEUTICS LLC

Changes to heart architecture through age, genetics, and/or lifestyle factors gradually weaken the hearts mechanical function and add stress to cardiac tissue.

Key Points: 
  • Changes to heart architecture through age, genetics, and/or lifestyle factors gradually weaken the hearts mechanical function and add stress to cardiac tissue.
  • Activation and upregulation of IL-1-dependent inflammation drives additional structural changes that further compromise heart function and contribute to the development and exacerbation of CVD.
  • Olatec is also pleased to report on another publication in CVD, covering dapansutriles new preclinical data demonstrating its cardio protective effects in this model.
  • Data in mice show significant preservation of contractile reserve and diastolic function in an experimental model of heart failure due to severe ischemic cardiomyopathy.

Interleukin Inhibitors Global Market Report 2021: Focus on IL-17, IL-23, IL-1, IL-5, IL-6, Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, Asthma, Inflammatory Bowel Disease - ResearchAndMarkets.com

Retrieved on: 
Wednesday, December 8, 2021
Health, Pharmaceutical, Johnson & Johnson, IL-6, Term of patent, Homeostasis, Inflammation, Biotechnology, Immunotherapy, Novartis, GlaxoSmithKline, Ustekinumab, Degenerative disease, Inflammatory bowel disease, Patient, Sanofi, IL, Psoriasis, Asthma, Lists of countries and territories, Secukinumab, Autoimmunity, Gedeon Richter, Rheumatoid arthritis, Canakinumab, COVID-19, Pharmacy, Interleukin, IL-5, Growth, AstraZeneca, Arthritis, Eli Lilly, Regeneron Pharmaceuticals, Roche, Teva Pharmaceuticals, Pharmaceutical industry

The "Interleukin Inhibitors Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Interleukin Inhibitors Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com's offering.
  • Major players in the interleukin inhibitors market are Sanofi, GlaxoSmithKline, Novartis, Johnson & Johnson, Roche, Eli Lilly, AstraZeneca, Teva Pharmaceutical, and Regeneron Pharmaceuticals.
  • The interleukin inhibitors market consists of the sales of interleukin inhibitors such as interleukin -1, interleukin -5, interleukin -6, interleukin -17, interleukin 23, by companies that manufacture them.
  • An increase in the number of investigational drugs for inflammatory diseases such as psoriasis, arthritis, and inflammatory bowel disease will drive the interleukin inhibitors market.

Tang Prize Laureates Reflect on the Breakthroughs Made Possible by Cytokine Research

Retrieved on: 
Saturday, November 27, 2021
World Health Organization, National academy, Emergency Use Authorization, Death, Juvenile idiopathic arthritis, Federation of European Pharmacological Societies, Cardiac myxoma, Signal transduction, Rheumatology, History, Risk, Nobel Prize, Castleman, World, Drug development, Lists of diseases, Food, IL-1, Interleukin-1 family, Degenerative disease, Lecture, Cancer, Mouth, Ventilation, Tocilizumab, Research, Castleman disease, TNF, News, National, Conference, Physiology, Medical school, TNFR1, Clinical trial, Human, COVID-19, Cytokine, Taipei Medical University, Interleukin 6, DRS, APFP, Tang Prize, Type 2 diabetes, Patient, Systemic, IL-1R, US Food Sovereignty Alliance, Inflammation, Translation, JIA, Novartis, Rheumatoid arthritis, IL-6, RNA, Canakinumab, Fibrosis, Pharmaceutical industry

Charles Dinarello, Marc Feldmann, and Tadamitsu Kishimoto, providing valuable informaiton on the role cytokines play in inflammation and the COVID-19 disease as well as possible treatments.

Key Points: 
  • Charles Dinarello, Marc Feldmann, and Tadamitsu Kishimoto, providing valuable informaiton on the role cytokines play in inflammation and the COVID-19 disease as well as possible treatments.
  • It was a journey that took them from basic research to drug development and clinical application.
  • These three lectures by the 2020 Tang Prize laureates in Biopharmaceutical Science will be premiered on the Tang Prize YouTube channel from 4 p.m. to 7 p.m. (GMT+8) on November 27.
  • To watch the complete version of the "2020 Tang Prize Laureate's Lectures for Biopharmaceutical Science," please consult the schedule below.

Interleukin Inhibitors Global Markets Report 2020-2030: Focus on IL-17, IL-23, IL-1, IL-5, IL-6 - ResearchAndMarkets.com

Retrieved on: 
Thursday, August 19, 2021
Health, Pharmaceutical, Secukinumab, Sanofi, Regeneron Pharmaceuticals, Gedeon Richter, Immunotherapy, Ustekinumab, Inflammation, Rheumatoid arthritis, Johnson & Johnson, Pharmacy, Teva Pharmaceuticals, Asthma, IL-5, Canakinumab, IL-6, Autoimmunity, Homeostasis, Psoriasis, Biotechnology, Degenerative disease, Lists of countries and territories, Patient, GlaxoSmithKline, Arthritis, Novartis, IL, Psoriatic arthritis, Roche, COVID-19, Eli Lilly, Interleukin, AstraZeneca, Inflammatory bowel disease, Pharmaceutical industry

The "Interleukin Inhibitors Global Market Report 2020-30: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Interleukin Inhibitors Global Market Report 2020-30: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering.
  • Major players in the interleukin inhibitors market are Sanofi, GlaxoSmithKline, Novartis, Johnson & Johnson, Roche, Eli Lilly, AstraZeneca, Teva Pharmaceutical and Regeneron Pharmaceuticals.
  • The interleukin inhibitors market consists of the sales of interleukin inhibitors such as interleukin -1, interleukin -5, interleukin -6, interleukin -17, interleukin 23, by companies that manufacture them.
  • Major companies in the interleukins sector are focusing on developing biosimilars for interleukin inhibitors.

Ilaris® receives Health Canada approval as first of its kind treatment for rare, inflammatory disorder, adult-onset Still's disease

Retrieved on: 
Thursday, April 29, 2021
Clinical medicine, Medicine, Medical specialties, Canakinumab, Immunology, Novartis, AOSD, Interleukin 1 beta, Monoclonal antibody, Adult-onset Still's disease

b'The approval of Ilaris (canakinumab) in the treatment of adult-onset Still\'s disease (AOSD) brings hope for Canadians living with this rare, debilitating, and sometimes life-threatening inflammatory disorder.\nDORVAL, QC, April 29, 2021 /CNW Telbec/ - Novartis Pharmaceuticals Canada Inc. is pleased to announce that Health Canada has approved Ilaris (canakinumab) for the treatment of active Still\'s disease, including adult-onset Still\'s disease (AOSD)1.

Key Points: 
  • b'The approval of Ilaris (canakinumab) in the treatment of adult-onset Still\'s disease (AOSD) brings hope for Canadians living with this rare, debilitating, and sometimes life-threatening inflammatory disorder.\nDORVAL, QC, April 29, 2021 /CNW Telbec/ - Novartis Pharmaceuticals Canada Inc. is pleased to announce that Health Canada has approved Ilaris (canakinumab) for the treatment of active Still\'s disease, including adult-onset Still\'s disease (AOSD)1.
  • "We are proud to announce this latest approval for Ilaris and are hopeful that it will open the door to reimagining care for adult Canadian patients.
  • "\nIlaris is a genetically engineered high-affinity human anti-human-interleukin-1 beta (IL-1) monoclonal antibody, administered by subcutaneous injection every four weeks in the treatment of AOSD1.
  • In our quest to find new medicines, we consistently rank among the world\'s top companies investing in research and development.